SEC Form 4 · accession 0001179110-18-000165
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dayton Misfeldt
Officer — Interim CEO · Director
Period of report
Dec 29, 2017
Accepted (ET)
Jan 2, 2018 · 8:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.69 | Dec 29, 2017 | A | 200,000 | A | — | Dec 29, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The option vests monthly over six (6) months in equal installments subject to optionee's continued service to the Company.